Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091103 · ClinicalTrials.gov registry record · Phase 2
Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01091103 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 60 participants.
The verdict
NCT01091103, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.
Interventions
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-02-18 |
| Est. Completion | 2013-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091103
The ClinicalTrials.gov registry entry for NCT01091103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Enzalutamide is the first listed.
NCT01091103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091103 about?
NCT01091103 is a clinical study titled "Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide". This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.
What is the current status of trial NCT01091103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-02-18. Estimated completion is 2013-08-31.
What interventions are being tested in trial NCT01091103?
The interventions under investigation include: Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT01091103?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.